# Re-evaluation Task: LUN-010

## Context
- **Case ID**: LUN-010
- **Cancer type**: Large cell neuroendocrine carcinoma (LCNEC) of the lung
- **Stage**: Stage IVB
- **Molecular profile**: RB1 loss, High Ki-67, SCLC-like molecular subtype (inferred from RB1 loss)
- **Report file**: experiment_reports\LUN-010_report.json
- **Current score**: 86/100
- **Gap analysis (local GPU)**: The most critical gaps in LUN-010's research report are the lack of data on Platinum-Etoposide + Immune Checkpoint Inhibitor combination therapy, which is a promising area of investigation for improving treatment outcomes in cancer patients. Filling this gap will improve the score by providing more comprehensive information on the efficacy and safety of this specific combination therapy, allowing researchers to better understand its potential as a treatment option.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  14/25  |  56.0% |
| rating_calibration                  |  13/15  |  86.7% |
| clinical_relevance                  |   9/10  |  90.0% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |
| source_quality                      |  15/15  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (56.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\LUN-010_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Large cell neuroendocrine carcinoma (LCNEC) of the lung",
    "stage": "Stage IVB",
    "molecular_profile": [
      "RB1 loss",
      "High Ki-67",
      "SCLC-like molecular subtype (inferred from RB1 loss)"
    ]
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Platinum-Etoposide + Immune Checkpoint Inhibitor (Atezolizumab/PD-1 Inhibitor)",
      "category": "Immunotherapy Combination",
      "composite_rating": 6.7,
      "rating_breakdown": {
        "evidence_level": {
          "score": 6,
          "rationale": "Retrospective real-world study (n=31) showed significant OS/PFS benefit. Extrapolated from IMpower133 Phase 3 in SCLC. ESMO 2023 poster on atezolizumab+PE in metastatic LCNEC. No prospective Phase 3 in LCNEC specifically, but strong biological rationale"
        },
        "survival_benefit": {
          "score": 7,
          "rationale": "ICIs+chemo: median OS 15.0 months vs 11.0 months chemo alone (p=0.036). Median PFS 10.5 vs 6.0 months (p=0.035). ORR 50% vs 29.4%. DCR 85.7% vs 76.5%. 49% reduction in progression risk (HR=0.51). Meaningful survival improvement over chemo alone"
        },
        "accessibility": {
          "score": 7,
          "rationale": "Atezolizumab FDA-approved for ES-SCLC (IMpower133). Off-label use for LCNEC requires oncologist discretion. Increasingly adopted at academic centers. Insurance coverage may require prior authorization for LCNEC indication"
        },
        "safety_profile": {
          "score": 7,
          "rationale": "In the LCNEC retrospective study, immune-related AEs were grade 1-2 only with no grade 3+ events observed. Favorable safety profile compared to chemo alone. Standard chemotherapy side effects plus manageable irAEs"
        },
        "biomarker_match": {
          "score": 7,
          "rationale": "LCNEC has median TMB of 9.9 mut/Mb supporting immunotherapy benefit. PD-L1 positive in 16% of stage IV LCNEC. RB1 loss/SCLC-like biology supports extrapolation from IMpower133. High Ki-67 indicates immunogenicity from rapid proliferation"
        }
      },
      "mechanism_of_action": "Platinum-etoposide chemotherapy induces immunogenic cell death releasing tumor neoantigens, while atezolizumab (anti-PD-L1) or PD-1 inhibitors block immune checkpoint pathways, preventing tumor immune evasion. The combination converts immunologically cold tumors to hot and unleashes T-cell-mediated anti-tumor responses.",
      "key_evidence": {
        "study_name": "First-line ICI + chemotherapy in advanced LCNEC (Frontiers in Oncology 2025)",
        "journal": "Frontiers in Oncology",
        "year": 2025,
        "sample_size": 31,
        "os_months": {
          "treatment": 15,
          "control": 11,
          "hazard_ratio": 0.55,
          "p_value": 0.036
        },
        "pfs_months": {
          "treatment": 10.5,
          "control": 6
        },
        "orr_percent": {
          "t
... (truncated — read full file from experiment_reports\LUN-010_report.json)
```
